Literature DB >> 3928746

Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma.

H W Murray, R A Gellene, D M Libby, C D Rothermel, B Y Rubin.   

Abstract

To test the hypothesis that tissue macrophages from AIDS patients have no intrinsic defects in either antimicrobial activity or in the capacity to respond to T cell-derived activating stimuli, alveolar macrophages from 11 patients were treated with crude lymphokines produced by healthy donors. After 72 hr of pretreatment with 10% mitogen- or antigen-induced crude lymphokines (which contained 300 U/ml of interferon-gamma [IFN-gamma]), AIDS alveolar macrophages generated twofold to threefold more H2O2 and readily inhibited the replication of the intracellular pathogens Toxoplasma gondii and Chlamydia psittaci. These responses were indistinguishable from those displayed by activated alveolar cells from 12 non-AIDS patients and three healthy volunteers. As judged by the abrogating effects of a neutralizing anti-human IFN-gamma monoclonal antibody, lymphokine-induced alveolar macrophage activation appeared to be largely IFN-gamma-dependent; thus, macrophages were also stimulated with recombinant (r)IFN-gamma alone. Seventy-two hours of treatment with 300 U/ml of rIFN-gamma resulted in both enhanced oxidative and antimicrobial activity comparable to that achieved by crude lymphokines, and the responsiveness of AIDS alveolar macrophages to rIFN-gamma was identical to control cells. These in vitro results suggest that tissue mononuclear phagocytes from AIDS patients a) are free of apparent defects in intracellular antimicrobial activity, b) are fully responsive to activating T cell products, and c) support the use of IFN-gamma as a potential macrophage-activating immunotherapeutic agent in AIDS-related opportunistic infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928746

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 2.  The immunocompromised host: HIV infection.

Authors:  James M Beck
Journal:  Proc Am Thorac Soc       Date:  2005

Review 3.  AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung.

Authors:  J R Clarke; D S Robinson; R J Coker; R F Miller; D M Mitchell
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 4.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3.

Authors:  A O Fels; C F Nathan; Z A Cohn
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

Review 6.  Innate immunity to Toxoplasma gondii infection.

Authors:  Felix Yarovinsky
Journal:  Nat Rev Immunol       Date:  2014-02       Impact factor: 53.106

Review 7.  Abnormalities of hematopoiesis in the acquired immunodeficiency syndrome.

Authors:  A Ganser
Journal:  Blut       Date:  1988-02

8.  Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients.

Authors:  F G Delemarre; A Stevenhagen; F P Kroon; M Y van Eer; P L Meenhorst; R van Furth
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  Alveolar macrophages in AIDS patients: increased spontaneous tumour necrosis factor-alpha production in Pneumocystis carinii pneumonia.

Authors:  V L Krishnan; A Meager; D M Mitchell; A J Pinching
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

Review 10.  Abnormalities in host defense associated with HIV infection.

Authors:  James M Beck
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.